title: Supratarsal injection of triamcinolone acetonide and childhood allergic keratoconjunctivitis.
abstract: To evaluate the efficacy and safety of supratarsal injection of triamcinolone acetonide in the treatment of refractory allergic keratoconjunctivitis in childhood. Thirty-five patients (70 eyes) with severe allergic keratoconjunctivitis were included in this study. Fifteen patients (42.8%) had atopic keratoconjunctivitis (AKC) and 20 (57.2%) had vernal keratoconjuncivitis (VKC). All patients underwent a bilateral supratarsal injection of 20 mg triamcinolone acetonide. Mean follow-up was 28 months (range 14-38). All patients showed a significant symptomatic improvement and partial resolution of clinical features of keratoconjunctivitis within the first 2 weeks. Corneal complications related to keratoconjunctivitis disappeared in all patients. One patient with VKC experienced ocular hypertension. No patient with AKC showed side-effects. Severe relapse of the disease was noted in 10% of eyes with VKC and in 6.7% of eyes with AKC after a mean follow-up of 9 and 11 months, respectively. Supratarsal injection of triamcinolone acetonide is effective and safe in patients with severe chronic allergic keratoconjunctivits to relieve severe inflammation associated with this disease.
authors.affiliation: Department of Ophthalmology, Fattouma Bourguiba University Hospital, 5019, Monastir, Tunisia.
authors.forename: Sonia
authors.initials: S
authors.lastname: Zaouali
authors.forename: Rim
authors.initials: R
authors.lastname: Kahloun
authors.forename: Sonia
authors.initials: S
authors.lastname: Attia
authors.forename: Bechir
authors.initials: B
authors.lastname: Jelliti
authors.forename: Manel
authors.initials: M
authors.lastname: Trigui
authors.forename: Salim Ben
authors.initials: SB
authors.lastname: Yahia
authors.forename: Riadh
authors.initials: R
authors.lastname: Messaoud
authors.forename: Moncef
authors.initials: M
authors.lastname: Khairallah
mesh_terms: D000293:Adolescent; D002648:Child; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D005143:Eyelids / Q000187:drug effects*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D014792:Visual Acuity / Q000502:physiology
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide